Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a party other than the Registrant   ☐

Check the appropriate box:

 ☐ Preliminary Proxy Statement

 ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

 ☐ Definitive Additional Materials

 ☐ Soliciting Material under §240.14a-12

 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

 ☐ Fee paid previously with preliminary materials

 ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

11 Great Valley Parkway

Malvern, PA 19355

April 25, 2025

During 2024, we continued to focus primarily on our modifier gene therapy programs—maximizing the Company’s financial resources and scientific know-how to get us closer to our goal of three Biologics License Applications (“BLA”) filings in the next three years—addressing major blindness diseases—and further positioning Ocugen as the leader in ophthalmology gene therapies. We advanced our ophthalmology clinical programs in line with enrollment and dosing timelines and are continuing to make significant progress in 2025.

The initiation of the OCU400 Phase 3 liMeliGhT clinical trial in the second quarter of 2024 was a pivotal event for Ocugen as a company and a significant milestone for patients with retinitis pigmentosa (“RP”). OCU400 is the first gene therapy program to enter a randomized Phase 3 clinical trial with a broad RP indication. Until now, there has been only one marketed product to treat one of the 100 potential gene mutations associated with RP. Now there is real hope for OCU400 to provide a one-time gene therapy for life to all 300,000 RP patients in the U.S. and Europe combined, and 1.6 million patients globally.

In August 2024, we announced approval for the expanded access program (“EAP”) for OCU400. The EAP makes OCU400 available to patients beyond our Phase 3 liMeliGhT clinical trial and extends enrollment to include patients representing a diverse array of RP gene mutations. This program reflects our ongoing commitment to develop a safe and effective therapy for RP patients who face the real prospect of losing their vision before a viable treatment option is made commercially available.

Long-term, 2-year safety and efficacy data from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in low luminance visual acuity (“LLVA”) in all evaluable treated subjects at two years when compared to untreated eyes. This data further supports the gene-agnostic mechanism of action of OCU400 with durability. We are enthusiastic about the potential of OCU400 to fulfill the existing significant unmet medical need associated with RP.

We are actively enrolling patients in the U.S. and Canada in the Phase 3 liMeliGhT clinical trial of OCU400 to remain on track to meet BLA and Marketing Authorization Approval (“MAA”) filing targets mid-2026.

The next candidate in line for BLA submission is OCU410ST for Stargardt disease in 2027. Stargardt disease has no approved therapies to rescue these patients from blindness today. Earlier this year the U.S. Food and Drug Administration (“FDA”) agreed to move forward with a single Phase 2/3 pivotal confirmatory clinical trial for OCU410ST registration, making it possible to potentially expedite our clinical development timeline by two to three years—compared to the traditional approach of Phase 2 followed by Phase 3—which should also allow us to save on significant development costs in taking this product to market to serve about 100,000 patients in the U.S. and Europe. The Phase 2/3 clinical trial will randomize 51 subjects, 34 of whom will receive a single, subretinal, injection of OCU410ST in the eye with worse visual acuity, and 17 of whom will serve as untreated controls. The primary endpoint in the clinical trial is change in atrophic lesion size. Secondary endpoints include visual acuity as measured by best corrected visual acuity (“BCVA”) and LLVA compared to untreated controls.

One-year data will be utilized for the BLA filing. OCU410ST Phase 1, six-month data demonstrated considerably slower lesion growth (54%) from baseline in treated eyes versus untreated fellow eyes and clinically meaningful 2-line (10-letter) improvement in visual function (BCVA), which is statistically significant (p=0.02). We plan to initiate the Phase 2/3 study by mid-year.

Finally, data from the Phase 1/2 OCU410 ArMaDa clinical trial shows promise to shift the paradigm from the current treatment approach for 2-3 million patients in the U.S. and Europe with geographic atrophy (“GA”), the late stage of dry AMD. Recent 12-month data from evaluable subjects in the Phase 1 study showed considerably slower lesion growth (41%) from baseline in treated eyes, increased preservation of retinal tissue around the GA lesions, and clinically meaningful 4-line (23-letter) improvement in LLVA in treated eyes compared to untreated eyes. Preservation of retinal tissue at 12 months compared favorably to published data on a leading FDA-approved complement inhibitor given monthly or every other month at the same time points. Most notably, currently approved treatments for GA have not shown significant benefit in visual function. Based on the science and preliminary data, we believe OCU410 has the potential to improve structural as well as functional outcomes with a one-time treatment for life for a disease that affects millions.

To support Ocugen’s clinical trials and extend the cash runway into the first quarter of 2026, the Company secured $65 million in equity/debt financings in the second half of 2024. Further supporting Ocugen’s efforts to enable long-term shareholder value, garner significant visibility within the investment community, and broaden the shareholder base, the Company was included in the Russell Index in May 2024. We are currently evaluating commercial partnership opportunities for OCU400.

From a people perspective, we strengthened the executive leadership team with the appointments of Dr. Huma Qamar as Chief Medical Officer and Ramesh Ramachandran as Chief Accounting Officer. Dr. Qamar’s appointment recognizes the important work she has done in building a strong clinical team and establishing relationships with leading medical and academic institutions and key opinion leaders. She continues to effectively manage all modifier gene therapy clinical trials, meeting important milestones along the way. Mr. Ramachandran is a seasoned and experienced finance professional who has held executive-level finance positions with both big, public multinational and private, mid-size organizations, as well as a private equity firm and Ernst & Young LLP, covering the Americas, Europe, and Asia. Since joining Ocugen, he has been instrumental in streamlining finance operations and supporting capital raises.

I would like to extend our gratitude and appreciation to our departing Board members, Prabhavathi Fernandes, Ph.D., FIDSA and Marna Whittington, Ph.D. for their contributions to Ocugen. I now look forward to welcoming Blaise Coleman and Satish Chandran, Ph.D. to the Board. Mr. Coleman brings significant leadership and financial expertise as former President, Chief Executive Officer, and Board Member at Endo, as well as holding senior leadership positions in finance at AstraZeneca and Johnson & Johnson. Dr. Chandran is a serial entrepreneur, having founded several biotech companies. Earlier in his career, he was Chief Technology Officer at Pfizer Biotherapeutics—OTU, where he led programs in oncology and metabolic diseases. He is the author of numerous scientific publications and holds multiple patents in the fields of vaccines, biologics, drugs and medical devices.

We have delivered on all our commitments—advancing clinical programs on time, delivering data to validate our revolutionary platform, and working with regulatory agencies to accelerate development so that patients, who are struggling with blindness disease, will have a potential rescue sooner than later. I am incredibly enthusiastic about Ocugen’s future. We now have all critical elements in place to bring our game-changing modifier gene therapies to market to potentially help millions of patients in need.

Thank you for your continued support,

​

 

​Shankar Musunuri, Ph.D., MBA​

Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen

THIS PROXY STATEMENT AND ENCLOSED PROXY CARD ARE

FIRST BEING MAILED TO STOCKHOLDERS ON OR ABOUT APRIL 25, 2025

You are invited to attend Ocugen, Inc.’s (the “Company,” “us,” “we,” “our,” or “Ocugen”) Annual Meeting of Stockholders (the “Annual Meeting”) on Thursday, June 5, 2025, at 8:00 a.m. Eastern Time.

This year’s Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via a live audio webcast. You will be able to attend the Annual Meeting online, vote electronically and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/OCGN2025.

At the Annual Meeting, stockholders will vote on:

​Stockholders will also transact any other business that may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

You are entitled to notice of the Annual Meeting (the “Notice”) and to vote at the Annual Meeting and any adjournments or postponements thereof only if you were a stockholder as of April 14, 2025 (the “Record Date”).

The board of directors (the “Board”) will give appropriate attention to written communications that are submitted by stockholders and other interested parties and will respond if and as appropriate.

We are pleased to comply with the rules of the Securities and Exchange Commission that allow companies to distribute their proxy materials over the Internet under the “notice and access” approach. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials, or Notice of Availablility, instead of a paper copy of our proxy materials and our Annual Report for the fiscal year ended December 31, 2024 (the “2024 Annual Report”). We will mail the Notice of Availability on or about April 25, 2025 and it contains instructions on how to access those documents and to cast your vote over the Internet. This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials. If you would like to receive a printed copy of our proxy materials, including our proxy statement, our 2024 Annual Report and a form of proxy card, free of charge, please follow the instructions on the Notice of Availablility. A copy of our 2024 Annual Report, except for exhibits, will be furnished without charge to any stockholder upon written request to Ocugen, Inc. 11 Great Valley Parkway Malvern, PA 19355, Attention: General Counsel. This proxy statement (“Proxy Statement”) and our Annual Report on Form 10-K for the fiscal year ended Decemeber 31, 2024 are also available on the SEC’s website at www.sec.gov. The Annual Meeting will be held virtually via live webcast on Thursday, June 5, 2025, at 8:00 a.m. Eastern Time.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS. THIS PROXY STATEMENT AND THE ENCLOSED PROXY CARD ARE FIRST BEING PROVIDED TO OUR STOCKHOLDERS ON OR ABOUT APRIL 25, 2025. IN ACCORDANCE WITH THE RULES OF THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), WE ARE ADVISING OUR STOCKHOLDERS OF THE AVAILABILITY ON THE INTERNET OF OUR PROXY MATERIALS RELATED TO OUR FORTHCOMING ANNUAL MEETING. THIS PROXY STATEMENT AND THE 2024 ANNUAL REPORT ARE AVAILABLE TO HOLDERS OF OUR COMMON STOCK AT WWW.PROXYVOTE.COM.

To assist you in reviewing this year’s proposals, we call your attention to the following proxy summary. This is only a summary; please review this Proxy Statement and our 2024 Annual Report in full.

 

 

The size of our Board is set at six members and is divided into three classes, each of which has a three-year term. Currently, class I, class II and class III consist of two directors each. You are being asked to vote on the election of class II directors, Uday Kompella, Ph.D. and Blaise Coleman, each to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or upon their earlier death, resignation, retirement, disqualification, or removal, and a class III director, Satish Chandran, Ph.D., to serve a one-year term expiring at the 2026 Annual Meeting of Stockholders and until his successor, if any, is elected or appointed, or upon his earlier death, resignation, retirement, disqualification, or removal.

Marna C. Whittington, Ph.D., a current class II director, previously notified us that she will not be seeking reelection, and her term will end effective as of the date of the Annual Meeting. We extend our gratitude and appreciation to Dr. Whittington for her contributions to Ocugen. If elected, Blaise Coleman will be a new director and successor to Dr. Whittington. Additionally, Prabhavathi Fernandes, Ph.D., FIDSA, a class III director, resigned from the Board effective at the Annual Meeting. If elected, Satish Chandran, Ph.D. will be a new director and successor to Dr. Fernandes.

Our directors are elected by a plurality of the votes cast by our stockholders at the Annual Meeting. If no contrary indication is made, shares represented by executed proxies will be voted FOR the election of Uday Kompella, Ph.D., Blaise Coleman, and Satish Chandran, Ph.D. Each of the nominees have agreed to serve as directors if elected, and we have no reason to believe that any of the nominees will be unable to serve.

The table below summarizes key qualifications, skills, or attributes of our continuing directors and director nominees. A mark indicates a specific area of focus or expertise on which the Board relies most in deciding whether to nominate a director to serve on our Board. The lack of a mark does not mean the director does not possess that qualification or skill. Each director’s biography below describes these qualifications and relevant experience in greater detail. We believe the table below demonstrates the breadth and diversity of the collective experience, expertise, and skills of our continuing directors and director nominees.

Our Board has established various committees (the “Committees”) to assist in discharging its duties: the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee, and the Science and Technology Committee. Each member of our Committees is an independent director as that term is defined by the SEC and The Nasdaq Capital Market (“Nasdaq”). Each of the Committees has the authority, as its members deem appropriate, to engage legal counsel or other experts or consultants in order to assist the Committee in carrying out its responsibilities. The Nominating and Corporate Governance Committee is responsible for overseeing periodic self-evaluations of the Board to determine whether it and its Committees are functioning effectively. Each Committee also conducts periodic self-evaluations of their own performance and reports their conclusions to the Board.

The Committee memberships and the primary responsibilities of each of the Committees are as follows:

The Audit Committee assists the Board by providing oversight of our financial management, independent auditor and accounting and financial reporting processes, as well as such other matters as directed by the Board or the Audit Committee Charter.

Among other things, the Audit Committee’s responsibilities include:

The current members of our Audit Committee are Dr. Whittington (Chair), Ms. Castillo, and Dr. Fernandes. All members of our Audit Committee are deemed “independent” and financially literate under the applicable rules and regulations of the SEC and Nasdaq. Dr. Whittington and Dr. Fernandes qualify as an “audit committee financial expert” within the meaning of SEC regulations. Dr. Fernandes’ and Dr. Whittington’s terms as members of the Audit Committee will expire at the Annual meeting. The Board intends to appoint Mr. Coleman and Dr. Chandran to the Audit Committee, if elected, and that Mr. Coleman will qualify as an “audit committee financial expert” within the meaning of SEC regulations.

The Compensation Committee reviews the performance and development of our management in achieving corporate goals and objectives and assures that our executive officers (including our Chief Executive Officer) are compensated effectively in a manner consistent with our strategy, competitive practice and stockholder interests, as well as such other matters as directed by the Board or the Compensation Committee Charter. Among other things, the Compensation Committee’s responsibilities include:

Our Compensation Committee may, in its sole discretion, retain or obtain the advice of compensation consultants, legal counsel or other advisors, after taking into consideration applicable factors affecting independence that are specified under Nasdaq and SEC regulations. Our Compensation Committee is directly responsible for the appointment, compensation and oversight of the work of any retained compensation consultant, legal counsel and other advisor, and is empowered, without further action by the Board, to both determine and cause us to pay such compensation to any retained compensation consultant, legal counsel and other advisor retained by the Compensation Committee. Our Chief Executive Officer annually reviews the performance of each of the other executive officers, including the other NEOs. He then recommends annual merit salary adjustments and any changes in annual or long-term incentive opportunities for other executives. The Compensation Committee considers our Chief Executive Officer’s recommendations in addition to data and recommendations presented by our executive compensation consultant.

Frederic W. Cook & Co., Inc. (“FW Cook”) continues to provide executive compensation consulting services. FW Cook presented a summary executive compensation report to the Compensation Committee, which included data about the compensation paid by the companies included in our peer group and other employers who compete with us for executives. Additionally, FW Cook has updated the Compensation Committee on new developments in areas that fall within the Compensation Committee’s jurisdiction and is available to advise the Compensation Committee regarding its responsibilities. FW Cook serves solely at the discretion of the Compensation Committee and their fees are approved by the Compensation Committee.

The current members of our Compensation Committee are Dr. Fernandes (Chair), Ms. Castillo, Dr. Kompella, and Dr. Whittington. Our Board has determined that all Compensation Committee members are independent under Nasdaq’s listing standards, and that they are “non-employee directors” for purposes of Rule 16b-3 under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Dr. Fernandes’ term as chair and member and Dr. Whittington’s terms as a member of the Compensation Committee will expire at the Annual Meeting.

The Nominating and Corporate Governance Committee identifies qualified individuals for membership on the Board, recommends to the Board the director nominees to fill vacancies on the Board and to stand for election at the next annual meeting of stockholders, develops and recommends to the Board a set of corporate governance guidelines for the Board and provides oversight of the corporate governance affairs of the Board, as well as such other matters as directed by the Board or the Nominating and Corporate Governance Charter. Among other things, our Nominating and Corporate Governance Committee’s responsibilities include:

The Nominating and Corporate Governance Committee is responsible for identifying individuals that the Committee believes are qualified to become Board members, as described below in the section entitled “Board Structure and Composition.” Our Corporate Governance Guidelines provide that diversity of background and experience should be considered in determining director candidates as well as other factors such as a candidate’s character, judgment, skills, education, expertise and absence of conflicts of interest. The Nominating and Corporate Governance Committee considers candidates proposed by our stockholders and reviews and evaluates information available to it regarding candidates proposed by stockholders and applies the same criteria, and follows substantially the same process in considering them, as it does in considering other candidates.

The members of our Nominating and Corporate Governance Committee are Ms. Castillo (Chair), Dr. Zhang, and Dr. Kompella. The Board has determined that all Nominating and Corporate Governance Committee members are independent under the listing standards of Nasdaq.

The Science and Technology Committee’s focus is to identify and assess business development opportunities that diversify and strengthen our product candidate portfolio. The Science and Technology Committee’s scientific expertise will actively provide direction to us in efforts to continue to expand on our mission of offering innovative solutions for unmet needs within healthcare. Among other things, our Science and Technology Committee’s responsibilities include:

The current members of our Science and Technology Committee are Dr. Kompella (Chair), Dr. Fernandes, Ms. Castillo, and Dr. Zhang. Our Board has determined that all Science and Technology Committee members are independent as set forth in Nasdaq’s listing standards. Dr. Fernandes’ term as a member of the Science and Technology Committee will expire at the Annual Meeting.

Our Board is our ultimate decision-making body, except with respect to those matters reserved to the stockholders. Our Board selects the members of our senior management team, who in turn are responsible for our day-to-day operations. Our Board acts as an advisor and counselor to senior management and oversees their performance.

Our Board consists of directors divided into three classes, with each class holding office for a three-year term. Uday Kompella, Ph.D. and Blaise Coleman have been nominated by our Board for election at the Annual Meeting for three-year terms that will expire at our 2028 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or upon their earlier death, resignation, retirement, disqualification, or removal. Additionally, Satish Chandran, Ph.D. has been nominated by our Board for election at the Annual Meeting for a one-year term that will expire at our 2026 Annual Meeting of Stockholders and until his successor, if any, is elected or appointed, or upon his earlier death, resignation, retirement, disqualification, or removal. Each of the nominees has agreed to be named and to serve, and we expect each nominee to be able to serve if elected. If any nominee is unable to serve, our Nominating and Corporate Governance Committee will recommend to our Board a replacement nominee. The Board may then designate the replacement nominee to stand for election. If you voted for the unavailable nominee, your vote will be cast for their replacement.

Marna C. Whittington, Ph.D. currently serves as a class II director of our Board with a term expiring at the Annual Meeting. Dr. Whittington previously informed the Board of her decision not to stand for re-election to the Board and her service as a member of our Board will end effective as of the date of the Annual Meeting. If elected, Blaise Coleman will be a new director and successor to Dr. Whittington. Additionally, Prabhavathi Fernandes, Ph.D., FIDSA, currently serves as a class III director of our Board with a term expiring at the 2026 Annual Meeting of Shareholders. Dr. Fernandes will resign from the Board effective at the Annual Meeting. If elected, Satish Chandran, Ph.D. will be a new director and successor to Dr. Fernandes.

The Nominating and Corporate Governance Committee of our Board is responsible for recommending the composition and structure of our Board and for developing criteria for Board membership. This Committee regularly reviews director competencies, qualities and experiences, with the goal of ensuring that our Board is comprised of an effective team of directors who function collegially and who are able to apply their experience toward meaningful contributions to our business strategy and oversight of our performance, risk management, organizational development and succession planning.

Our Bylaws provide that the number of members of our Board shall be fixed by the Board from time to time. Our Board is currently fixed at six members. Our Board is divided into three classes with staggered three-year terms. The Nominating and Corporate Governance Committee is responsible for identifying individuals that the Committee believes are qualified to become Board members.

The following table summarizes our current Board structure and key elements of our corporate governance framework:

The Nominating and Corporate Governance Committee has identified certain criteria that it will consider in identifying director nominees. Important general criteria and considerations for Board membership include:

In each of the director biographies above, we highlight the specific experience, qualifications, attributes and skills that led the Board to conclude that each director is qualified to serve on our Board.

Our Corporate Governance Guidelines provide that diversity of background and experience should be considered in determining director candidates as well as other factors such as a candidate’s character, judgment, skills, education, expertise and absence of conflicts of interest. However, we do not have a formal policy concerning the diversity of the Board. Our priority in selection of board members is identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. The Nominating and Corporate Governance Committee and the full Board are committed to creating a board of directors that promotes our strategic objectives and fulfills its responsibilities to our stockholders, and considers diversity of background, education, professional experience, and differences in viewpoints and skills when evaluating proposed director candidates.

Under Nasdaq’s listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Our Board consults with our legal counsel to ensure that the Board’s determinations are consistent with all relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent Nasdaq listing standards, as in effect from time to time.

Our Board has determined that all our current directors, except for Dr. Musunuri, and each nominee for director are, or as the case may be, will be “independent” directors, as defined under the rules of Nasdaq. In making such determination, our Board considered the relationships that each such non-employee director has with us and all other facts and circumstances that our Board deemed relevant in determining his or her independence, including the beneficial ownership of our common stock by each non-employee director. Our independent directors generally meet in an executive session at each regularly scheduled Board meeting.

There are no arrangements or understandings between any of our director nominees, directors or executive officers and any other person pursuant to which any director nominee, director or executive officer was or is to be selected as a director nominee, director or executive officer, as applicable. Other than Mr. Coleman, the former President and Chief Executive officer of Endo International plc, which filed a petition for bankruptcy on behalf of itself and its subsidiaries in August 2022, no director has been involved in any legal proceedings required to be disclosed under Item 401(f) of Regulation S-K.

As presently constituted, the Board represents a deliberate mix of members who have a deep understanding of our business, as well as members who have different skill sets and points of view.

Also, in 2023, we created a LID role with robust duties, such as presiding over the executive sessions of the Board, the authority to call meetings of the independent directors and serving as the principal liaison between the Chairman and the independent directors, among other duties, to ensure the Board’s independent oversight of management. The Board appointed Prabhavathi Fernandes, Ph.D., FIDSA as LID. Upon her resignation the LID role will be vacant.

During 2024, the Board met six times; its Audit Committee met eight times; its Compensation Committee met four times; its Nominating and Corporate Governance Committee met five times; and its Science and Technology Committee met four times.

Each member of our Board attended 75% or more of the aggregate of (i) the total number of meetings of the Board, and (ii) the total number of meetings held by the committees of the Board on which he or she served, during the portion of the fiscal year ended December 31, 2024 for which he or she was a director or committee member.

Directors are encouraged, but not required, to attend our annual stockholder meetings. All of the directors attended the 2024 Annual Meeting of Stockholders.

During 2024, Dr. Kompella, Dr. Fernandes, Ms. Castillo, and Dr. Whittington served as members of our Compensation Committee. During 2024 and as of the date of this report, none of the members of the Compensation Committee was or is one of our officers or employees, and none of our executive officers has served or serves on the Compensation Committee or Board of any company that employed or employs any member of our Compensation Committee or Board.

The Board is committed to continuous improvement and annual self-evaluation is an important tool for evaluating effectiveness. The Board and each Committee conducts rigorous annual self-evaluations of their performance and effectiveness.

 

We have designed and implemented our compensation program for our non-employee directors to attract, motivate, and retain individuals who are committed to our values and goals and who have the expertise and experience that we need to achieve those goals. Our Compensation Committee periodically reviews our compensation program for non-employee directors, including how our non-employee director compensation compares to our peer group and market trends.

Under our compensation program for our non-employee directors as in effect for 2024, each non-employee member of our Board was entitled to the following compensation:

In December 2024, based on the recommendation of our Compensation Committee, our Board amended the non-employee director compensation policy to decrease the grant date fair value of the annual and initial equity grants from $170,000 to $115,000.

The following table presents the total compensation for each of our non-employee directors who served as a member of our Board during the fiscal year ended December 31, 2024. Dr. Musunuri did not receive any additional compensation for his service as the Chairman of our Board. Dr. Musunuri’s compensation as an employee is described under “Executive Compensation” below. Mr. Coleman and Dr. Chandran, did not serve on our Board in 2024 and, as such, did not receive any compensation as directors during the fiscal year ended December 31, 2024.

Director Stock Ownership Guidelines. To further align the interests of our directors, executive officers and our stockholders, the Board adopted stock ownership guidelines in March 2022. In the case of our non-employee directors, the guidelines require that each director owns shares of our common stock that have an aggregate fair market value equal to or greater than five times the annual base cash retainer. Individuals have five years after first becoming subject to the guidelines to attain the requisite level of stock ownership.

The following table sets forth the name, position, and age of each of our executive officers as of the date of this Proxy Statement:

The Board is committed to fostering a strong culture of compliance and ethical conduct and has structured its Committees and their activities to support this commitment. The Board supports management’s promotion of a corporate culture of integrity, ethical behavior, and compliance with laws and regulations, and ensures that our culture and strategy are aligned. The Board expects all directors, as well as officers and employees, to conduct themselves in a manner consistent with our Code of Conduct and our values. The Board believes that a strong culture of integrity, ethics, and compliance is fundamental to the conduct of our business, and is necessary for managing risk, maintaining investor trust, and ensuring corporate governance.

In fiscal year 2024, our notable ESG highlights include:

We are committed to good corporate governance and integrity in our business dealings. Our governance practices are documented in our Charter, our Bylaws, our Code of Conduct, our Corporate Governance Guidelines and the charters of the Committees. Aspects of our governance documents are summarized below. You can find the charter for each Committee of the Board and our Code of Conduct on our website at https://ir.ocugen.com/corporate-governance.

We have a written set of Corporate Governance Guidelines that are designed to help ensure effective corporate governance of our Company. Our Corporate Governance Guidelines cover topics including, but not limited to, director responsibilities, director qualification standards, director access to management and independent advisors, director compensation, director orientation and continuing education, the periodic evaluations of our Board and its Committees and succession planning. Succession planning for the Board is critical to our success. Our goal is to achieve a Board that provides effective oversight of the Company through the appropriate balance of diversity of perspectives, experience, expertise and skills. Our Corporate Governance Guidelines are reviewed periodically by the Nominating and Corporate Governance Committee to assess the adequacy of the corporate governance guidelines and recommend any proposed changes to the Board. The Corporate Governance Guidelines are amended by our Board when appropriate. The full text of our Corporate Governance Guidelines is available on our website at https://ir.ocugen.com/.

The Board’s role in risk oversight is consistent with our leadership structure, with management having day-to-day responsibility for assessing and managing our risk exposure and the Board actively overseeing management of our risks, both at the Board and Committee level. The risk oversight process includes receiving

regular reports from Committees and our executive officers to enable our Board to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, cybersecurity, finance, legal, regulatory, strategic and reputational risk.

The Board focuses on the overall risks affecting us. Each Committee has been delegated the responsibility for the oversight of specific risks that fall within its areas of responsibility. For example:

While each Committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through Committee reports about such risks. Matters of significant strategic risk are considered by our entire Board.

We have a written Code of Conduct that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Conduct covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of our property, compliance with legal and regulatory requirements and internal reporting procedures for violations of the code. The Code of Conduct is available on our website at https://ir.ocugen.com/corporate-governance and any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website or in a Current Report on Form 8-K which we will file with the SEC.

Only the Board may waive any specific provision of this Code of Conduct for directors and executive officers. The compliance officer may waive any specific provision of this Code of Conduct for employees other than directors and executive officers. In the event of an approved waiver involving the conduct of a director or executive officer, appropriate and prompt disclosure, including disclosure of the reasons for the waiver, must be made to our stockholders as required by applicable law and Nasdaq rules. The Board shall be responsible for monitoring compliance with the Code of Conduct and shall assess the adequacy of the Code of Conduct periodically and approve any changes to the Code of Conduct.

It is our policy to comply with applicable insider trading laws, rules and regulations, and any exchange listing standards when engaging in transactions in our securities.

Our insider trading policy applies to all of our employees, including our executive officers and directors. The policy, among other things, prohibits (i) trading in call or put options involving our securities and other derivative securities; (ii) engaging in short sales of our securities; (iii) holding our securities in a margin account or pledging our securities to secure margin or other loans; and (iv) engaging in any forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts.

Our Board adopted an amended and restated compensation recovery policy effective as of September 15, 2023, in compliance with the Nasdaq listing rules, which requires recovery from executive officers of incentive-based compensation that is earned, granted or vested based on the achievement of a financial reporting measure in the event of a required accounting restatement of previously issued financial statements. The recoverable compensation includes any compensation received after the effective date of the compensation recovery policy and in the three-year fiscal period preceding the date we were required to prepare the accounting restatement that is in excess of the amount that would have been earned, paid or vested had it been calculated based on the restated financial statements. Recovery is required regardless of fault or a covered officer’s role in the financial reporting process. The compensation recovery policy has been filed as Exhibit 97 to our Annual Report on Form 10-K for the year ended December 31, 2023. At no time during or after the year ended December 31, 2024, was the company required to prepare an accounting restatement that required recovery of erroneously awarded compensation pursuant to the compensation recovery policy, nor was there, on December 31, 2024, an outstanding balance of erroneously awarded compensation to be recovered from the application of the policy to a prior restatement.

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who beneficially own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than 10% beneficial owners are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

To our knowledge, based solely on our review of Forms 3, 4 and 5, and any amendments thereto, filed by such reporting persons and/or written representations that no Form 5 was required, we believe that during the fiscal year ended December 31, 2024, all filing requirements applicable to our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities under the Exchange Act were met in a timely manner except for two late Form 4 filings for Arun Upadhyay, Ph.D. each reporting one transaction of a sale of common stock, and one late Form 4 filing by Prabhavathi Fernandes, Ph.D., FIDSA reporting one transaction to purchase common stock.

There are no family relationships among any of our directors or executive officers.

Our Board has adopted a Related Party Transactions Policy setting forth the policies and procedures for the review and approval or ratification of related party transactions. This policy covers any financial transactions, arrangements, or relationships, or any series of similar transactions, arrangements, or relationships, in which we were or are to be a participant in which any related person had, has, or will have a direct or indirect material interest. Our management team is responsible for determining whether a transaction is a related party transaction subject to our policy, and upon such determination, is responsible for disclosing the material facts concerning the transaction and the related party’s interest in the transaction to our Audit Committee. In reviewing and approving any such transactions, our Audit Committee is required to consider all available relevant facts and circumstances with respect to the transaction and shall evaluate all available options, including ratification, revision, or termination of the transaction. All of the transactions described under “Certain Relationships and Related Party Transactions” below were either approved or ratified in compliance with our Related Party Transactions Policy.

Described below are any transactions occurring since January 1, 2023 and any currently proposed transactions to which (i) the amount involved exceeded, or will exceed, $120,000 (or, if less than $120,000, 1% of the average of our total assets on December 31, 2023 and 2024); (ii) we were a party; and (iii) a director, executive officer, holder of more than 5% of our outstanding capital stock, or any member of such person’s immediate family that has or will have a direct or indirect material interest in the transaction, other than the compensation, termination, and change in control arrangements that are described in the “Executive Compensation” section.

For information on employment arrangements and compensation for service as our officers or on our Board, see “Director Compensation” and “Executive Compensation” sections of this Proxy Statement.

Our Charter and Bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law. We also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that we will indemnify the officer or director, under the circumstances and to the extent provided for in the agreement, for expenses, damages, judgments, fines, and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer, or other agent of us, and otherwise to the fullest extent permitted under Delaware law and our Charter and Bylaws.

At the Annual Meeting, our stockholders will vote on the election of two class II director nominees each named in this Proxy Statement as a director, to serve until our 2028 Annual Meeting of Stockholders and until their respective successors are elected and qualified, and one class III director nominee named in this Proxy Statement as a director, to serve until our 2026 Annual Meeting of Stockholders and until his respective successor is elected and qualified. Our Board has unanimously nominated Uday Kompella, Ph.D. and Blaise Coleman as class II directors and Satish Chandran, Ph.D. as a class III director for election to our Board at the Annual Meeting.

Each of the nominees has agreed to be named and to serve, and we expect each nominee to be able to serve if elected. If any nominee is unable to serve, the Nominating and Corporate Governance Committee will recommend to our Board a replacement nominee. The Board may then designate the replacement nominee to stand for election. If you voted for the unavailable nominee, your vote will be cast for their replacement.

 

 

The Audit Committee has appointed and engaged PwC to serve as our independent registered public accounting firm to audit our consolidated financial statements for the 2025 fiscal year and to perform audit-related services.

The Audit Committee works with our management in order to negotiate appropriate fees with our independent registered public accounting firm and is ultimately responsible for approving those fees. The following is a summary and description of fees for services provided by our independent registered public accounting firms, PwC and Ernst & Young LLP (“Ernst & Young”), in fiscal year 2024 and Ernst & Young, in fiscal year 2023. Other than as set forth below, no professional services were rendered, or fees billed by PwC and Ernst & Young during fiscal year 2024 or by Ernst & Young during fiscal year 2023.

“Audit Fees” means the fees billed or incurred by PwC and Ernst & Young for the year ended December 31, 2024 and by Ernst & Young for the year ended December 31, 2023 for professional services rendered in connection with the annual audit, and quarterly reviews of our consolidated financial statements for the years ended December 31, 2024, and 2023, and the fees billed in connection with the filing of registration statements with the SEC.

“Audit-Related Fees” consisted of amounts paid to PwC and Ernst & Young for the year ended December 31, 2024 and to Ernst & Young for the year ended December 31, 2023 for assurance and related services reasonably related to the performance of the audit or review of the financial statements and that are not reported under the “Audit Fees” category. There were no such fees incurred during the years ended December 31, 2024, or 2023.

“Tax Fees” consisted of amounts paid to PwC and Ernst & Young for the year ended December 31, 2024 and to Ernst & Young for the year ended December 31, 2023 for tax compliance and consulting. There were no such fees incurred during the years ended December 31, 2024, or 2023.

The Audit Committee is responsible for appointing, setting compensation for, and overseeing the work of our independent registered public accounting firm. The Audit Committee Charter establishes a policy that all audit and permissible non-audit services provided by our independent registered public accounting firm, PwC, will be pre-approved by the Audit Committee. The Audit Committee can pre-approve specified services in defined categories of audit services and audit-related services up to specified amounts as part of the Audit Committee’s approval of the scope of the engagement of PwC or on an individual case-by-case basis before PwC is engaged to provide a service. All such audit services were pre-approved in accordance with this policy during the fiscal year ended December 31, 2024. PwC has not been engaged to perform any non-audit services or tax services.

As previously disclosed, on May 31, 2024, Ernst & Young notified us of its decision to decline to participate in the request-for-proposal process and to decline to stand for re-election as our independent registered public accounting firm for fiscal year 2024, which decision was not the result of any disagreement with us.

The reports of Ernst & Young on our consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports of Ernst & Young on our consolidated financial statements as of and for the years ended December 31, 2023 and 2022 contained an explanatory paragraph which noted that we had suffered recurring losses from operations and there was substantial doubt as to our ability to continue as a going concern, and the audit report of Ernst & Young on our consolidated financial statements as of and for the year ended December 31, 2023 contained an explanatory paragraph related to the restatement of the 2022 consolidated financial statements.

During the years ended December 31, 2023 and 2022, and the subsequent interim period through May 31, 2024, there were (i) no disagreements between us and Ernst & Young on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which, if not resolved to Ernst & Young’s satisfaction, would have caused Ernst & Young to make reference to the subject matter of the disagreement in connection with its report for such years, and (ii) no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S-K for such years and subsequent interim period through May 31, 2024, except for Ernst & Young’s communication of the material weakness in internal control over financial reporting as of December 31, 2023, as described in Part II, Item 9A (Controls and Procedures) of our Annual Report on Form 10-K for the year ended December 31, 2023, relating to the design and operating effectiveness of controls over the accounting for collaborative arrangements.

During the fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through May 31, 2024, neither our company nor anyone acting on its behalf consulted Ernst & Young regarding the application of accounting principles to a specified transaction, either completed or proposed or the type of audit opinion that might be rendered on our financial statements or any matter that was either the subject of a disagreement (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to that Item) or a reportable event (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

As a result of this process and in connection with evaluating the proposals from participating firms, on July 2, 2024, the Board approved the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2024 as Ernst & Young ceased providing services following the filing of our Form 10-Q for the quarter ending June 30, 2024.

During the two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through July 2, 2024, neither us nor anyone on our behalf consulted with PwC with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided to us that PwC concluded was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

Ernst & Young has furnished our company with a letter addressed to the SEC stating that it agrees with the above statements, a copy of which is filed as Exhibit 16.1 to our Current Report on Form 8-K filed with the SEC on June 6, 2024.

The Audit Committee has reviewed and discussed the audited consolidated financial statements for the fiscal year ended December 31, 2024, with management and our independent registered public accounting firm, PwC. The Audit Committee has discussed with PwC the matters required to be discussed by the applicable requirements of the auditing standards of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. The Audit Committee has also received the written disclosures and the letter from PwC required by applicable requirements of the PCAOB regarding PwC’s communications with the Audit Committee concerning independence and has discussed with PwC the firm’s independence. Based on the foregoing, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in our 2024 Annual Report for filing with the SEC.

Ocugen, Inc.

Audit Committee

Chair: Marna C. Whittington, Ph.D.

Prabhavathi Fernandes, Ph.D., FIDSA

Kirsten Castillo, MBA

The Audit Committee has appointed and engaged PwC to serve as our independent registered public accounting firm to audit our consolidated financial statements for the 2025 fiscal year and to perform audit-related services. Stockholders are hereby asked to ratify the Audit Committee’s appointment of PwC as our independent registered public accounting firm for the 2025 fiscal year.

The Audit Committee is solely responsible for selecting our independent auditors. Although stockholder ratification of the appointment of PwC to serve as our independent registered public accounting firm is not required by law or our organizational documents, the Board has determined that it is desirable to seek stockholders’ ratification as a matter of good corporate governance in view of the critical role played by independent registered public accounting firms in maintaining the integrity of financial controls and reporting. If the stockholders do not ratify the appointment of PwC, the Audit Committee will reconsider its selection and whether to engage an alternative independent registered public accounting firm.

Representatives of PwC are expected to attend the Annual Meeting where they will be available to respond to appropriate questions and, if they desire, to make a statement.

The following table shows for the years ended December 31, 2024, and 2023 the compensation awarded to, paid to, or earned by our 2024 NEOs, who include our Chief Executive Officer, our two other most highly compensated executive officers who were serving as of December 31, 2024, and up to two additional individuals for whom disclosure would have been provided but for the fact that such individual was no longer serving as an executive officer as of December 31, 2024.

Our NEOs include:

(7)   The amounts reported consist of (i) the annual cash bonuses earned by Dr. Qamar in the amount of $158,362 and (ii) a one-time sign-on bonus paid in connection with Dr. Qamar’s commencement of employment with us in amount of $100,000.

The compensation paid during the year ended December 31, 2024 to Ocugen’s NEOs who are employees, consisted of the following components:

Direct compensation for our NEOs who are employees primarily consists of three principal components: base salary, annual cash incentive opportunities, and equity based long-term incentive (“LTI”) awards.

Base salary represents the fixed portion of an executive officer’s compensation and is intended to provide compensation for day-to-day performance. The Compensation Committee believes that a competitive base salary is a necessary element of any compensation program that is designed to attract and retain talented and experienced executives. Base salaries are reviewed annually, typically in connection with the annual performance review process, and adjusted from time to time to take into account market levels, individual responsibilities, performance, and experience.

For the 2024 fiscal year, the annual base salary for Dr. Musunuri, Dr. Upadhyay, and Dr. Qamar was equal to $757,900, $466,200 and $435,000, respectively.

The Compensation Committee believes that performance-based cash incentive bonuses play an important role in providing incentives to executives to achieve annual corporate goals. For fiscal year 2024, the Compensation Committee approved target annual incentive bonuses and developed a framework for determining the payout percentage.

Each NEO who is an employee has a target annual cash incentive amount, which is expressed as a percentage of his or her salary. This target is set forth in each such NEO’s employment agreement and is evaluated by our Compensation Committee annually based upon a review of the peer group and industry data provided by FW Cook, as well as other items used in the process for determining executive officer compensation, as described above. From time to time, our Board or Compensation Committee may approve other discretionary or formulaic annual bonuses for the NEOs based on corporate performance for our chief executive officer and corporate and individual performance for our other NEOs, as otherwise determined to be appropriate.

For the 2024 fiscal year, our Board approved annual incentive targets for Dr. Musunuri, Dr. Upadhyay, and Dr. Qamar, which was equal to 66%, 45%, and 45%, respectively, of such NEO’s annual base salary.

The corporate performance metrics for 2024 included advancing product pipeline and clinical development, focused business development, operational and manufacturing excellence, and financial execution, corporate responsibility and talent management. Even though all three gene therapies progressed well in the clinic and our Year to Date (“YTD”) total shareholder return (“TSR”) (64%) was higher than the Nasdaq Biotechnology Index’s YTD TSR (6%), the Compensation Committee considered overall business factors including cash runway

and market conditions, and recommended fraction of target bonus as corporate performance. Based on this corporate performance recommendation, our Board approved $385,165 as the bonus for our Chief Executive Officer, Dr. Musunuri. The Compensation Committee approved $169,720 and $158,362 as the bonus for our NEOs, Dr. Upadhyay, and Dr. Qamar, based on corporate as well as individual performance metrics.

We believe that equity grants provide our NEOs with a strong link to long-term performance and retention incentives, create an ownership culture, and help to align the interests of executive officers and stockholders.

Our general practice has been to grant stock option awards to each executive officer at the start of employment and on an annual basis for performance and retention purposes. Stock options or other equity-based awards may also be granted for the accomplishments of specific milestones. The size and value of annual equity awards are based on considerations included in the process for determining executive compensation, and for 2024, were based in part on the recommendations of FW Cook. Historically, our long-term incentive (“LTI”) max consisted of 50% RSUs and 50% time-based stock options. In response to stockholder feedback, in December 2023, the Compensation Committee approved a new LTI mix for 2024, which changed from 50% RSUs and 50% time-based stock options to 50% performance share awards (“PSAs”) and 50% time-based stock options. The PSAs are earned based on the achievement of pre-established performance metrics over a three-year performance period, further aligning executive compensation with the Company’s long-term strategic goals and stockholder value creation.

The following table summarizes the number of shares of our common stock underlying outstanding equity awards for each of our NEOs as of December 31, 2024.